Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

250.18

+1.36 (0.54%)

as of Jul 21, 2026, 4:03:27 pm Market Open.

697 watching

Investor Insights

Jul 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown strong performance in the pharmaceutical sector, particularly after spinning off its orthopedics division. Despite challenges in the cardio business and ongoing talcum-cancer lawsuits, expert opinions are largely optimistic about the company's future prospects. The current focus on high-margin areas like medical devices and pharmaceuticals, combined with a strong drug pipeline, positions JNJ for growth. Although the stock may experience fluctuations around earnings reports, it is generally viewed as a buy during dips. Overall, experts suggest that JNJ remains a sound investment, particularly for those interested in dividend growth and potential additional upside.

Consensus

Buy

Valuation

Fair Value

Similar

HOLD

Allan Tong’s Discover Picks Bulls points to a robust balance sheet and a dividend that has risen for 50 straight years. JNJ is more diversified than its peers, operating in consumer products, diagnostics (for surgeries which have been rebounding since the spring lockdown) as well as drugs. It also trades at a reasonable 22.5x PE and pays a 2.78% dividend. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.

Wealthica Track your Stocks in your Watch List

TOP PICK

It has three businesses – Pharma, devices and personal care. It is a great story because if one is doing poorly, the other two aren’t. 16 times earnings and a great increasing, dividend for 54 years in a row. They are working on a COVID vaccine.

DON'T BUY

One of the companies going through a vaccine trial. They were in the news recently because they had to pause trials due to an illness in a test participant. However, it is not just about the vaccine. They have consumer, pharma and medical device. There is still litigation list from the talc issue. It trades at 15x earnings, which is reasonable but it does take into account vulnerabilities. He prefers BDX.

HOLD

JNJ vs. ABT Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

DON'T BUY

They boast a great pipeline of drugs that it overshadows their Covid efforts. Problem is the stock jumped above $150 ahead of next week's quarterly report--the bar has been raised, but he prefers lower expectations.

PAST TOP PICK

(A Top Pick Oct 15/19, Up 14%) His model price is $201 or a 37% upside. They are in phase three trials with a COVID-19 vaccine.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly In the search for a pandemic vaccine, JNJ is a potential winner. Leveraging off their proven technology with their Ebola, HIV and other vaccines, the company continues to develop a COVID-19 vaccine that presently shows strong immunity response in 99% of trials. It is also the only option that is testing a single-dose vaccine. Revenues have dipped 10% in the latest quarterly earnings, but that can be attributed to a slow down in elective procedures. It pays a good dividend backed by a 67% payout ratio. We would trade this with a stop-loss at $132. Yield 2.75% (Analysts’ price target is $165.06)

TOP PICK

Raised dividend for 57 years. Nice balance between drug business, consumer products, and diagnostics. Likely to see acquisitions in consumer and diagnostics. A beneficiary of the post-Covid environment. Long-term exposure to a global healthcare leader. Good valuation. Continued performance. Yield is 2.08%. (Analysts’ price target is $163.63)

BUY ON WEAKNESS

Just announced it started its phase 3 trial of its Covid vaccine. JNJ offers real value. You can buy a tranche tomorrow then more if it goes down.

TOP PICK

A diversified healthcare name. The pharma drug pipeline is robust with success launching products that should continue. Strong balance sheet and pays under a 3% yield that they've increased in 50 straight years. The medical devices unit got hit by the lockdown, but surgeries are coming back (they reportedly snapped back to 85% pre-Covid). They are developing a vaccine, but won't make a profit, they say, in the first stage. (Analysts’ price target is $163.63)

DON'T BUY

It's not cyclical enough to thrive. They're diversified in pharma (drugs) and medical devices. The former benefited from the lockdown from a stockpile in meds they were able to still sell, but now he doesn't know if medical devices can fully benefit from the backlog of surgeries that is being addressed now. Doesn't know if JNJ leads in medical devices. Also, JNJ isn't cyclical, which is where should be flowing. JNJ is trying to respond to the rise of robotic surgery by Intuitive Surgical, which he prefers. This take time and research for JNJ, which means Intuitive will still be ahead of JNJ. JNJ as a defensive will underperform cyclicals, which is where the market is heading as we exit this recession.

TOP PICK

Unique healthcare company with its 3 divisions: medical devices, personal products, pharma. Last quarter, medical devices were challenged. US election risk. Just bought Momenta. JNJ is a great company that continues to execute. Litigation risks are successfully defended. Covid vaccine deal. Good valuation. Yield is 2.70%. (Analysts’ price target is $163.58)

BUY

Owns JNJ instead of Pfizer, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

PAST TOP PICK

(A Top Pick Jul 29/19, Up 10%) He would stick with this one. When a vaccine comes forward, he expects them to bounce up. His model price is $203 -- over 40% upside.

COMMENT

JNJ vs ABBV? He likes JNJ as a long term winner. It may be too expensive. ABBV was a risky company until they purchased Allergan and diversified their business more. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. They are still tethered to Humara, which has a lot of generics being developed. He would favor ABBV, although it is a little riskier than JNJ.

Showing 166 to 180 of 628 entries

Most Recent Experts

Julien Nono-Womdim

Goodreid Investment Council

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)